SMIM17

Across TCGA pan-cancer cohorts, SMIM17 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SMIM17’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where SMIM17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SMIM17 is over-expressed in tumor, although a few such as LUAD and BLCA show the opposite, repressed pattern.

CHOL, KIRC, and LIHC are the cancer types where SMIM17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SMIM17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	+0.688	<.001	3	view →
KIRC	All	All	+0.166	.001	3	view →
LIHC	All	All	+0.114	<.001	3	view →
LUAD	Female	III,IV	−0.314	.025	1	view →
BLCA	Male	IV	−0.285	.024	1	view →
KIRP	Male	All	−0.268	.003	1	view →
STAD	All	All	−0.217	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SMIM17–CHOL

Open the CHOL breakdown →